- Home
- AIN vs CNTA Comparison
AIN vs CNTA Comparison
Compare AIN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIN
- CNTA
- Stock Information
- Founded
- AIN 1895
- CNTA 2020
- Country
- AIN United States
- CNTA United Kingdom
- Employees
- AIN N/A
- CNTA N/A
- Industry
- AIN Textiles
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- AIN Consumer Discretionary
- CNTA Health Care
- Exchange
- AIN Nasdaq
- CNTA Nasdaq
- Market Cap
- AIN 2.5B
- CNTA 2.3B
- IPO Year
- AIN 1987
- CNTA 2021
- Fundamental
- Price
- AIN $80.28
- CNTA $17.14
- Analyst Decision
- AIN Buy
- CNTA Strong Buy
- Analyst Count
- AIN 4
- CNTA 7
- Target Price
- AIN $82.75
- CNTA $23.71
- AVG Volume (30 Days)
- AIN 254.5K
- CNTA 688.3K
- Earning Date
- AIN 10-30-2024
- CNTA 11-12-2024
- Dividend Yield
- AIN 1.30%
- CNTA N/A
- EPS Growth
- AIN 1.31
- CNTA N/A
- EPS
- AIN 3.20
- CNTA N/A
- Revenue
- AIN $1,267,294,000.00
- CNTA $6,853,000.00
- Revenue This Year
- AIN $9.42
- CNTA N/A
- Revenue Next Year
- AIN $4.54
- CNTA N/A
- P/E Ratio
- AIN $25.06
- CNTA N/A
- Revenue Growth
- AIN 15.93
- CNTA N/A
- 52 Week Low
- AIN $67.39
- CNTA $6.65
- 52 Week High
- AIN $99.41
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- AIN 49.94
- CNTA 51.71
- Support Level
- AIN $79.92
- CNTA $15.88
- Resistance Level
- AIN $83.06
- CNTA $18.12
- Average True Range (ATR)
- AIN 1.86
- CNTA 0.95
- MACD
- AIN -0.41
- CNTA -0.09
- Stochastic Oscillator
- AIN 24.29
- CNTA 44.17
About AIN Albany International Corporation
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.